Skip to main content

A Biotech ETF at the Center of a Profit/Peril Market

The liver diseases known as NASH, the primary cause of transplants of that vital organ, should be on investors’ radars and the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) is the ETF perhaps best situated to capitalize on what could become an almost $10 billion market. SBIO focuses on...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.